How can obesity treatments move beyond GLP-1 drugs to offer long-term, patient-friendly solutions? Obesity management is at a pivotal phase, with new opportunities emerging to deliver sustainable weight loss. Globally, 650 million people have obesity, with this number projected to almost double by 2025, further exasperating the considerable burden for patients. While GLP-1 drugs have gained significant traction, the next wave of innovation will shape the future of treatment. But what will it look like? In a landscape where convenience, safety, and efficacy are paramount, finding the right solutions requires exploring beyond the status quo. This session will introduce emerging technologies and treatment modalities, such as CB1-inhibition, dual-hormone approaches, microbiome-targeting therapies, and hormone release restoration that hold the potential to disrupt the market. Industry experts will discuss how these next-gen therapies pave the way for safer, long-lasting weight management, all while improving patient quality of life.